EyeTherapy Blog News

Athena Vision launches; developing gene therapies for devastating eye diseases

Tue, 24 Nov 2015 11:53:39 +0000

Athena Vision is focused on developing gene therapies for eye diseases based on research conducted at UCL Today sees the launch of Athena Vision Limited a biopharmaceutical company focused on the development of gene therapies to treat a range of devastating eye diseases causing blindness. Launched by UCL Business PLC, the wholly-owned technology transfer company of UCL, […]


Registration for Retina Day 2015 Now Open!

Wed, 10 Jun 2015 11:37:25 +0000

It’s that time once agin for our annual research day for patients and the public. Retina Day 2015 is a free, one day event is organised by the Gene and Cell Therapy Group, UCL Institute of Ophthalmology and NIHR Moorfields Biomedical Research Centre. Come along to: * Hear about some of the latest innovations in research […]


UCL RPE65 Gene Therapy Trial Shows Benefit in People with Leber Congenital Amaurosis Type 2 for up to Three Years After Treatment

Tue, 05 May 2015 14:44:39 +0000

We are delighted to be able to announce that yesterday, Monday 4th May, the long-term results of our RPE65 gene therapy trial for Leber Congenital Amaurosis Type 2 (LCA2) were published in the prestigious New England Journal of Medicine. Begun in 2007, this was the world’s first-in-human trial of gene therapy to treat an inherited […]


Gene therapy for uveitis

Uveitis is a leading cause of sight loss amongst those of working age. Find out about how you can support our work and help develop effective therapies.

Uveitis is a group of conditions in which the immune system attacks the body's own cells, leading to damaging inflammation and loss of sight. The eye's local immune system is normally tightly regulated by a balance of cells and molecules that prevent large-scale inflammation; caused by many different triggers depending on whether the front of the back of the eye is affected, uveitis results from a failure of this tight regulation. 

Uveitis can give rise to inflammation in the blood vessels serving the back of the eye (left), white spots known as keratic precipitates forming on the inner surface of the cornea (right), and many other forms of inflammatory damage to the eye

Uveitis is a common condition for which existing treatments have limitations - they are short-acting and are often systemically delivered, and chronic use can have significant side-effects. We are therefore developing longer-acting, locally-administered treatments based on viral gene therapy.

We have shown that delivering genes that help control the immune system locally in the eye can prevent the most damaging types of inflammation seen in models of uveitis, and are improving the effectiveness of gene therapy for uveitis through ongoing studies.

Page last modified on 03 dec 12 11:11